224 related articles for article (PubMed ID: 33219461)
1. Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience.
Hosono N; Ookura M; Araie H; Morita M; Itoh K; Matsuda Y; Yamauchi T
Int J Hematol; 2021 Mar; 113(3):362-369. PubMed ID: 33219461
[TBL] [Abstract][Full Text] [Related]
2. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Immunol; 2021; 12():683595. PubMed ID: 34484181
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation.
Genthon A; Brissot E; Malard F; van de Wyngaert Z; Bonnin A; Banet A; Marjanovic Z; Ikhlef S; Lapusan S; Sestili S; Corre E; Paviglianiti A; Adaeva R; 'Hammedi-Bouzina FM; Labopin M; Dulery R; Mohty M; Legrand O
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):791-796. PubMed ID: 32741743
[TBL] [Abstract][Full Text] [Related]
4. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
Cortes JE; de Lima M; Dombret H; Estey EH; Giralt SA; Montesinos P; Röllig C; Venditti A; Wang ES
J Hematol Oncol; 2020 Oct; 13(1):137. PubMed ID: 33059764
[TBL] [Abstract][Full Text] [Related]
5. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
7. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.
Niktoreh N; Lerius B; Zimmermann M; Gruhn B; Escherich G; Bourquin JP; Dworzak M; Sramkova L; Rossig C; Creutzig U; Reinhardt D; Rasche M
Haematologica; 2019 Jan; 104(1):120-127. PubMed ID: 30093401
[TBL] [Abstract][Full Text] [Related]
8. The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.
Açar İH; Guvenc B
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984499
[No Abstract] [Full Text] [Related]
9. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
Rafiee R; Chauhan L; Alonzo TA; Wang YC; Elmasry A; Loken MR; Pollard J; Aplenc R; Raimondi S; Hirsch BA; Bernstein ID; Gamis AS; Meshinchi S; Lamba JK
Blood Cancer J; 2019 May; 9(6):51. PubMed ID: 31113932
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
[TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
[TBL] [Abstract][Full Text] [Related]
12. Gemtuzumab Ozogamicin in
Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
[TBL] [Abstract][Full Text] [Related]
13. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
Fournier E; Duployez N; Ducourneau B; Raffoux E; Turlure P; Caillot D; Thomas X; Marceau-Renaut A; Chantepie S; Malfuson JV; Lemasle E; Cheok M; Celli-Lebras K; Guerin E; Terré C; Lambert J; Pautas C; Dombret H; Castaigne S; Preudhomme C; Boissel N
Blood; 2020 Feb; 135(8):542-546. PubMed ID: 31880804
[TBL] [Abstract][Full Text] [Related]
14. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
15. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation: A case report.
Sumiyoshi R; Tashiro H; Saito S; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
Medicine (Baltimore); 2020 Aug; 99(35):e22064. PubMed ID: 32871966
[TBL] [Abstract][Full Text] [Related]
18. The evolving use of gemtuzumab ozogamicin in acute myeloid leukemia.
Walter RB
Clin Adv Hematol Oncol; 2021 Mar; 19(3):152-154. PubMed ID: 33739963
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
[TBL] [Abstract][Full Text] [Related]
20. Association of fludarabin, cytarabine, and fractioned gemtuzumab followed by hematopoietic stem cell transplantation for first-line refractory acute myeloid leukemia in children: A single-center experience.
Penel-Page M; Plesa A; Girard S; Marceau-Renaut A; Renard C; Bertrand Y
Pediatr Blood Cancer; 2020 Jun; 67(6):e28305. PubMed ID: 32307866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]